We recently published a list of Top 10 Insider Purchases Last Month. In this article, we are going to take a look at where Metsera, Inc. (NASDAQ:MTSR) stands against other top insider purchases last ...

Metsera ,” said Whit Bernard, CEO. “We advanced MET-097i, our monthly, fully-biased GLP-1 RA injectable, from f ...

Equities research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for Metsera in a report issued on Thursday, March 27th. Cantor Fitzgerald analyst P. Agrawal now ...

After an IPO this year, Metsera is making its best effort to catch up to obesity drug giants Eli Lilly and Novo Nordisk.

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs ...

The newly listed clinical-stage biotechnology company, Metsera Inc. MTSR rose 15.01% on Monday as the broader markets declined. What Happened: While the company reported insider trades over the ...

Metsera, Inc. (NASDAQ:MTSR) is also one of 10 stocks insiders spent the most money on recently. Overall, MTSR ranks 8thon our list of stocks with at least $10 million in insider spending recently.

Explore Metsera stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for MTSR. Science Applications Posts Better-Than-Expected Earnings, Joins Qifu Technology ...

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic ...

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid ...

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid and ...